Compare ARVN & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | OMDA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | 943 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 978.5M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | OMDA |
|---|---|---|
| Price | $8.95 | $17.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 11 |
| Target Price | $15.05 | ★ $21.73 |
| AVG Volume (30 Days) | 858.9K | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $24.96 |
| Revenue Next Year | N/A | $20.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $10.28 |
| 52 Week High | $14.22 | $26.92 |
| Indicator | ARVN | OMDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 70.80 |
| Support Level | $8.72 | $14.39 |
| Resistance Level | $10.18 | $19.26 |
| Average True Range (ATR) | 0.47 | 0.86 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 28.82 | 84.64 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.